Oslo, Norway, 28 September 2023: Photocure, The Bladder Cancer Company,
announces changes to the composition of its Board of Directors. Reference is
made to the stock exchange notice on 9 August 2023 and that Jan H. Egberts, M.D.
has decided to step down from his position as Chairperson of the Company's Board
of Directors. Dr. Egberts has now resigned from the Board of Directors of
Photocure ASA.

The current board members of Photocure will constitute the Board of Directors
after Dr. Egberts' resignation until the general meeting elects a new Board of
Directors. Further, the members of the Board of Directors have, after
consultation with the nomination committee, resolved that current board member
Dylan Hallerberg will take the position as interim Chairperson of the Board of
Directors until such election is made.

The nomination committee has initiated a search for a new Chairperson, and it is
expected that the committee will present its recommendations to the annual
general meeting in 2024 at the latest.

For further information, please contact:

Erik Dahl
Chief Financial Officer
Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com